Here is our weekly deals update that focuses on IPO, funding, and deal news across medical devices and biotechnology. News includes sleep apnea, diagnostics, ADCs, and more. Congratulations to everyone involved.
NextCure has ramped up its antibody-drug conjugate pivot, penning a $745 million deal for the ex-China rights to Simcere Zaiming’s phase 1-stage tumor asset.
Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep Apple Therapeutics to access small molecules against a non-incretin GPCR target.
Obstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118
Aortyx announced today that it brought in $16 million (€13.8 million) to support its bioresorbable aortic patch technology.
A biomarker discovery and diagnostics startup has been awarded £860,000 in funding from Innovate UK. The investment for Tagomics comes as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from the UK’s innovation agency.
Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.
BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion.
Spain’s SpliceBio will use $135 million from a series B round backed by Sanofi and Roche to advance its lead gene editing therapy for Stargardt disease through clinical studies.
Atraverse Medical has raised $29.4 million to fund its minimally invasive system for accessing the inner chambers of the heart, with plans to expand its commercial reach and set up new products in its R&D pipeline.
Exoskeleton developer Wandercraft has raised $75 million in new financing shortly after inking a strategic partnership with French auto manufacturer Renault.
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.
